Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза III Россия

ALX1-11 (drug)

An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)

Номер протоколаCL1-11-002
ФазаФаза III
Участников по плану — во всех странах исследования1 683
Сроки16.10.2001 — 13.04.2005
Начало: 16 октября 2001Окончание: 13 апреля 2005
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00172133/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: от 45 лет, только женщины. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 1683 чел. во всех странах исследования.
  • Центров в реестре: 2 в одном городе. Список — ниже на странице.
  • Плановая дата окончания (04.2005) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возрастот 45 лет
ПолТолько женщины
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 10 · невключение: 51

Критерии включения

  • Women who completed 18 months of treatment in Protocol ALX1-11-93001; or
  • Women prematurely discontinued from Protocol ALX1-11-93001 who want to participate in OLES for the events listed below must have their clinical course reviewed and approved by the CAB for enrollment into the OLES:
  • Clinical or incident lumbar vertebral fractures as assessed by the central imaging organization
  • Clinical or incident hip fracture
  • Confirmed bone loss at A/P lumbar vertebra or total hip or femoral neck as assessed by the central imaging organization
  • Body weight below 40 kg
  • Development of an exclusion criterion in Protocol ALX1-11-93001
  • It must be accepted by patients whose clinical courses are reviewed by the CAB that participation in OLES may require additional tests at baseline and/or during the study to ensure their utmost safety.
  • Women with the ability to self-administer a daily injection or have a designee who will give the injections;
  • Women who are capable of understanding and giving written, voluntary informed consent before the start of open-label dosing with ALX1-11.

Критерии невключения

  • A. History or Concurrent Illness:
  • Disorders of Immunity Endocrine system Gastrointestinal system Kidney and collecting system Liver, biliary tract and pancreatic systems Musculoskeletal system
  • Patients with chronic, active joint disease requiring more than one intra-articular injection every 6 months Neoplasia
  • Patients who have had squamous or basal cell carcinoma of the skin may enter this study if:
  • The lesion(s) were fully resected with clear margins described in a written report by a pathologist, and
  • The patient has had no recurrence of lesions for at least one year from the time of the original resection.
  • Nervous system Vascular, respiratory and cardiac system *Significant diseases or disorders are determined by history, physical exam or laboratory tests and judged by the Principal Investigator to be significant.
  • B. Concurrent Medication:
  • Patients may not use any of the following therapies while they are enrolled in this OLES without permission from the Sponsor and the PMO:
  • Tetracycline antibiotics for four weeks prior to bone biopsy
  • Any PTH analogs \[e.g., rhPTH(1-84), PTH(1-34), PTHrP and analogs\]
  • Fluoride
  • Strontium
  • Phenytoin for seizure control
  • Any investigational drug other than ALX1-11
  • Anabolic steroids or androgens
  • Active Vitamin D3 metabolites and analogs, e.g., calcitriol
  • Systemic corticosteroids, more than 5 mg/day prednisone or a systemic corticosteroid formulation equivalent to 5 mg/day prednisone
  • 1\. A patient who has been enrolled into the OLES and needs to receive an acute bolus of steroids (oral or injectable) for a self-limited illness may continue treatment in the study if the following requirements are met:
  • Exposure to steroids will be limited to no more than 30 consecutive days
  • The maximal dose of steroid (prednisone equivalent) must be limited to no more than 225 mg (7.5 mg each day for 30 days)
  • The illness is acute in nature and is not expected to recur during the remaining period of the study
  • Bisphosphonates, including investigational bisphosphonates
  • Calcitonin
  • Estrogen replacement therapy by oral, transdermal or intramuscular administration
  • SERM drugs, e.g., tamoxifen, raloxifene, Evista
  • Vaginal application of estrogen-containing creams unless the dose is:
  • conjugated estrogen or estradiol: maximum of 0.5 g twice each week (total of 1.0 g weekly)
  • Estrace (Ogen): maximum of 1.0 g twice each week (total of 2.0 g weekly)
  • Daily inhaled corticosteroid unless dose is equivalent to <1200 µg/day of beclomethasone
  • Cytostatics, e.g., azathioprine, recombinant human tumor necrosis fusion (Fc) protein, monoclonal antibody against tumor necrosis factor (e.g., remicade \[infliximab\]
  • Methotrexate
  • The antimetabolite, methotrexate, which interferes with DNA synthesis, repair and cellular replication should not be used by patients participating in this OLES.
  • In general, immunomodulatory agents with antiproliferative activity are not permitted as a concomitant medication in this OLES.
  • Intra-articular injections
  • 1\. Patients may receive a maximum of one intra-articular injection (ONE JOINT ONLY) every 6 months while participating in this OLES. The joint that is injected may be a different joint every 6 months. The dose of corticosteroid injected should not exceed the anti-inflammatory equivalent dose of Prednisone 40 mg suspension. The dose and volume should be adjusted downward as appropriate to the size of the joint.
  • Provera is an acceptable concomitant medication when used according to the label instructions
  • Patients may be enrolled in this OLES if they have been stabilized on the following therapy for the specified amount of time:
  • Thyroid Hormone (<0.1 mg/day thyroxine) therapy for at least 6 months If taking > 0.1 mg/day but < 0.2 mg/day, must have serum TSH level 1. > 0.1mU/L. Patients will be excluded if they are taking doses of > 0.2 mg/day.
  • 2\. However, if a patient has had a minimal change in L-thyroxine dose of < 0.025 mg/day within 6 months of the baseline visit, and has been on this new dose for at least 2 months, the patient may be enrolled in this study. The patient's history with L-thyroxine must be clearly documented in the source documents.
  • 3\. If a patient requires an increase in their thyroid replacement dose, as recommended by a physician who is caring for the patient, after enrollment in this OLES, the patient must have a TSH and T4 level within 3 months of the dose change to ensure the patient does not become hyperthyroid
  • Stable dosage of thiazide for at least 3 consecutive months
  • C. Laboratory Values and Physical Examination Findings:
  • \- Serum calcium greater than 10.7 mg/dL (2.66 mmol/L) at baseline will be managed as outlined in Appendix 4
  • \- Urinary calcium to creatinine ratio greater than or equal to 1 at baseline will be managed as outlined in Appendix 5
  • Elevated total serum alkaline phosphates (> 400 U/L) at baseline will be managed as outlined in Appendix 6 except as noted for Latin and South American countries.
  • Any other clinically significant abnormal value as judged by the investigator
  • D. Substance Abuse:
  • Alcohol and/or drug abuse
  • E. Compliance:
  • Suspected or confirmed poor compliance in completing clinical trial evaluations and/or clinical trial required questionnaires

Источник: ClinicalTrials.gov, NCT00172133 · запись обновлена в реестре 17 мая 2021.

Дизайн и результаты

ДизайнНерандомизированное, открытое (без ослепления), одна группа; цель — лечение
Включено участников (факт, все страны)1 683
Результатыв реестре не опубликованы
Что измеряют — первичные конечные точки (1), вторичных — 1
  • To evaluate the safety of continued dosing with ALX1-11, up to a maximum of 24 months, in postmenopausal osteoporotic women who participated in Protocol ALX1-11-93001 (TOP). — 24 months of treatment

Цель исследования

This is an Open Label Extension Study (OLES) for patients who participated in the 18 month double-blind, placebo-controlled, Phase III trial (Protocol ALX1 11 93001 the TOP Study) studying the effect of ALX1-11, recombinant human parathyroid hormone, rhPTH(1-84), on vertebral fracture incidence. The primary objective of this study is to evaluate the safety of continued dosing with ALX1-11, up to a maximum of 24 months, in postmenopausal osteoporotic women who participated in Protocol ALX1 11 93001.

Где проходит

2 центра в 1 городе

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00172133 Официальный реестр (США) · загружено 9 ноября 2026
    Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.